
|Videos|March 15, 2011
Dr. Langmuir on Vandetanib in Medullary Thyroid Cancer
Author(s)Peter Langmuir, MD
Advertisement
Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca on Vandetanib in Medullary Thyroid Cancer
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































